Federal Register / Vol. 73, No. 36 / Friday, February 22, 2008 / Notices 9819 

Related Publications: 

1. A manuscript directly related to 

this technology will be available as soon 

as it is accepted for publication. 

2. E Calvo. Collagen-platelet 

aggregation inhibitor from mosquito 

salivary glands. Biacore T100 seminar 

series, November 2006, St. Louis, 

Missouri. 

3. S Yoshida and H Watanabe. Robust 

salivary gland-specific transgene 

expression in Anopheles stephensi 

mosquito. Insect Mol Biol. 2006 Aug; 

15(4):403–410. 

4. D Sun et al. Expression of 

functional recombinant mosquito 

salivary apyrase: a potential therapeutic 

platelet aggregation inhibitor. Platelets. 

2006 May; 17(3):178–184. 

Patent Status: U.S. Provisional 

Application No. 60/198,629 filed 09 Jul 

2007 (HHS Reference No. E–172–2007/ 

0–US–01); U.S. Provisional Application 

No. 60/982,241 filed 24 Oct 2007 (HHS 

Reference No. E–172–2007/1–US–01) 

Licensing Status: Available for 

exclusive or non-exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases, Laboratory of 

Malaria and Vector Research, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize the platelet aggregation 

inhibitor Aegyptin. Please contact Dr. 

Jose Ribeiro, Head, Vector Biology 

Section, at 301–496–9389 or 

jribeiro@niaid.nih.gov for more 

information. 

Manganese Superoxide Dimutase 

VAL16ALA Polymorphism Predicts 

Resistance to Doxorubicin Cancer 

Therapy 

Description of Technology: Cancer is 

the second leading cause of death in the 

United States and it is estimated that 

there will be approximately 600,000 

deaths caused by cancer in 2006. Major 

drawbacks of the existing cancer 

therapies are the interindividual 

differences in the response and the 

cytotoxic side-effects that are associated 

with them. Thus, there is a need to 

develop new therapeutic approaches to 

optimize treatment and increase patient 

survival. 

This technology describes the 

identification of a manganese 

superoxide dismutase (MnSOD) 

polymorphism as a novel biomarker for 

the prognosis of doxorubicin 

therapeutic response in breast cancer 

patients, wherein a Val16Ala 

polymorphism of MnSOD is indicative 

of patient survival. More specifically, 

patients undergoing doxorubicin 

combination therapy with Val/Val, Val/ 

Ala, and Ala/Ala genotypes had 95.2%, 

79%, and 45.5% survival rates, 

respectively, in a case study of 70 

unselected breast cancer patients. 

Carriers of the Ala/Ala genotype had a 

highly significantly poorer breast 

cancer-specific survival in a 

multivariate Cox regression analysis 

than carriers of the Val/Val genotype. 

This technology can be developed into 

an assay to screen for breast cancer 

patients who will be responsive to 

doxorubicin treatment. Further, as the 

MnSOD polymorphism is common in 

the population (15% to 20% of patients 

have the Ala/Ala genotype), it is a 

common risk factor for doxorubicin 

therapy. This technology can potentially 

be utilized as a screening tool applicable 

for all cancer types treated with 

doxorubicin. 

Applications: 

A novel genetic marker that can 

predict breast cancer patient survival 

with doxorubicin treatment. 

A screening test based on MnSOD 

Val16Ala genotype that predicts patient 

response to doxorubicin cancer therapy, 

wherein treatment can be subsequently 

individualized according to patient 

MnSOD genotype. 

Development Status: Future studies 

include determining the mechanism in 

which the polymorphism modulates 

doxorubicin toxicity. 

Inventors: Stefan Ambs and Brenda 

Boersma (NCI). 

Patent Status: U.S. Provisional 

Application No. 60/799,788 filed 11 

May 2006 (HHS Reference No. E–137–

2006/0–US–01); PCT Application No. 

PCT/US2007/068588 filed 09 May 2007 

(HHS Reference No. E–137–2006/0–

PCT–02). 

Licensing Status: Available for nonexclusive or exclusive licensing. 

Licensing Contact: Jennifer Wong; 

301/435–4633; wongje@mail.nih.gov. 

Collaborative Research Opportunity: 

The Laboratory of Human 

Carcinogenesis, Center for Cancer 

Research, National Cancer Institute, 

National Institutes of Health, is seeking 

statements of capability or interest from 

parties interested in collaborative 

research to further develop, evaluate, or 

commercialize MnSOD genotyping 

assays to assess a patient’s response to 

doxorubicin combination therapy. 

Please contact John D. Hewes, PhD, at 

301–435–3121 or hewesj@mail.nih.gov 

for more information. 

Dated: February 15, 2008. 

David Sadowski, 

Deputy Director, Division of Technology 

Development and Transfer, Office of 

Technology Transfer, National Institutes of 

Health. 

[FR Doc. E8–3274 Filed 2–21–08; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Cancer Institute; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Initial Review Group, Subcommittee 

A — Cancer Centers. 

Date: April 22–23, 2008. 

Time: 8 a.m. to 2:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Crown Plaza Silver Spring, 8777 

Georgia Avenue, Silver Spring, MD 20910. 

Contact Person: Gail J. Bryant, MD, 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, 6116 Executive Blvd, Room 8107, 

MSC 8328, Bethesda, MD 20892–8329, (301) 

402–0801, gb30t@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: February 14, 2008. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 08–794 Filed 2–21–08; 8:45 am] 

BILLING CODE 4140–01–M 

mstockstill on PROD1PC66 with NOTICES